Β-lactam allergy: Difference between revisions
From IDWiki
Β-lactam allergy
(Imported from text file) |
No edit summary |
||
| Line 1: | Line 1: | ||
= Beta-lactam allergies = |
== Beta-lactam allergies == |
||
== Cross-reactivity == |
=== Cross-reactivity === |
||
{| class="wikitable" |
|||
{| |
|||
! |
! |
||
!align="center"| C-7 G1 |
!align="center"| C-7 G1 |
||
| Line 233: | Line 233: | ||
|} |
|} |
||
=== C-7 Side Chains === |
==== C-7 Side Chains ==== |
||
* '''Group 1:''' penicillin, cephalothin, cefoxitin |
* '''Group 1:''' penicillin, cephalothin, cefoxitin |
||
| Line 239: | Line 239: | ||
* '''Group 3:''' cefipime, cefotaxime, ceftriaxone |
* '''Group 3:''' cefipime, cefotaxime, ceftriaxone |
||
=== C-3 Side Chains === |
==== C-3 Side Chains ==== |
||
* '''Group 1:''' cefadroxil, cephalexin |
* '''Group 1:''' cefadroxil, cephalexin |
||
| Line 253: | Line 253: | ||
Drugs that have identical R1 or R2 structures are listed as R1 (red cell) or R2 (gold cell). If only the ring or branch chain moiety of the R1 structure is identical, it is listed as R10 or R100, respectively. Drugs that have similar R1 or R2 structures are listed as r1 or r2. If only the ring or branch chain moiety of the R1 structure is similar, it is listed as r10 or r100, respectively. Blank cells imply no R1 or R2 structural similarities. |
Drugs that have identical R1 or R2 structures are listed as R1 (red cell) or R2 (gold cell). If only the ring or branch chain moiety of the R1 structure is identical, it is listed as R10 or R100, respectively. Drugs that have similar R1 or R2 structures are listed as r1 or r2. If only the ring or branch chain moiety of the R1 structure is similar, it is listed as r10 or r100, respectively. Blank cells imply no R1 or R2 structural similarities. |
||
== Hypersensitivity Reactions == |
=== Hypersensitivity Reactions === |
||
* Type I (IgE-mediated) |
* Type I (IgE-mediated) |
||
| Line 267: | Line 267: | ||
** Penicillins '''should be avoided''' |
** Penicillins '''should be avoided''' |
||
== Further Reading == |
=== Further Reading === |
||
* Zagursky RJ and Pichichero ME.[http://dx.doi.org/10.1016/j.jaip.2017.08.027 Cross-reactivity in β-Lactam Allergy]. ''J Allergy Clin Immunol Pract''. 2018;6(1):72-81.e1. |
* Zagursky RJ and Pichichero ME.[http://dx.doi.org/10.1016/j.jaip.2017.08.027 Cross-reactivity in β-Lactam Allergy]. ''J Allergy Clin Immunol Pract''. 2018;6(1):72-81.e1. |
||
Revision as of 15:03, 17 August 2019
Beta-lactam allergies
Cross-reactivity
| C-7 G1 | C-7 G2 | C-7 G3 | C-3 G1 | C-3 G2 | C-3 G3 | C-3 G4 | C-3 G5 | C-3 G6 | C-3 G7 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Penicillin | X | |||||||||
| Ampicillin | X | |||||||||
| Amoxicillin | X | |||||||||
| Cefazolin | ||||||||||
| Cephalexin | X | X | ||||||||
| Cefadroxil | X | X | ||||||||
| Cephalothin | X | X | ||||||||
| Cefotetan | X | |||||||||
| Cefoxitin | X | X | ||||||||
| Cefuroxime | X | |||||||||
| Cefaclor | X | |||||||||
| Cefotaxime | X | X | ||||||||
| Ceftriaxone | X | |||||||||
| Ceftazidime | X | |||||||||
| Cefixime | X | |||||||||
| Cefdinir | ||||||||||
| Cefipime | X | |||||||||
| Ceftaroline |
C-7 Side Chains
- Group 1: penicillin, cephalothin, cefoxitin
- Group 2: amoxicillin, ampicillin, cefaclor, cephalexin, cefadroxil
- Group 3: cefipime, cefotaxime, ceftriaxone
C-3 Side Chains
- Group 1: cefadroxil, cephalexin
- Group 2: cefotetan
- Group 3: cefotaxime, cephalothin
- Group 4
- Group 5: cefuroxime, cefoxitin
- Group 6: cefixime
- Group 7: ceftazidime
Comparison of R1 and R2 structural similarities between b-lactam drugs
Drugs that have identical R1 or R2 structures are listed as R1 (red cell) or R2 (gold cell). If only the ring or branch chain moiety of the R1 structure is identical, it is listed as R10 or R100, respectively. Drugs that have similar R1 or R2 structures are listed as r1 or r2. If only the ring or branch chain moiety of the R1 structure is similar, it is listed as r10 or r100, respectively. Blank cells imply no R1 or R2 structural similarities.
Hypersensitivity Reactions
- Type I (IgE-mediated)
- Anaphylaxis
- Itchy rash
- Penicillins should be avoided
- Type II (IgG-mediated)
- Non-itchy rash
- Rash will improve if treatment continues, no need to avoid penicillins
- Type IV (cell-mediated)
- Toxic epidermal necrolysis
- Stevens-Johnson syndrome
- Penicillins should be avoided
Further Reading
- Zagursky RJ and Pichichero ME.Cross-reactivity in β-Lactam Allergy. J Allergy Clin Immunol Pract. 2018;6(1):72-81.e1.
